Phibro Animal Health (NASDAQ:PAHC) Stock Price Down 4.3% – Should You Sell?

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC) dropped 4.3% during mid-day trading on Thursday . The stock traded as low as $38.26 and last traded at $38.2050. 37,577 shares were traded during trading, a decline of 87% from the average daily volume of 296,314 shares. The stock had previously closed at $39.92.

Analysts Set New Price Targets

Several brokerages recently weighed in on PAHC. Weiss Ratings lowered Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, June 15th. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Finally, Citigroup reduced their target price on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. One research analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Phibro Animal Health has an average rating of “Hold” and a consensus target price of $47.67.

Phibro Animal Health Stock Performance

The company has a current ratio of 2.96, a quick ratio of 1.27 and a debt-to-equity ratio of 1.84. The firm’s 50-day moving average is $34.62 and its two-hundred day moving average is $41.95. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of 15.79, a P/E/G ratio of 1.11 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, August 26th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.14. Phibro Animal Health had a return on equity of 37.86% and a net margin of 6.57%.The company had revenue of $396.75 million for the quarter, compared to analysts’ expectations of $381.18 million. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. As a group, sell-side analysts expect that Phibro Animal Health Corporation will post 3.51 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Wednesday, September 2nd will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s payout ratio is presently 19.67%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PAHC. Cetera Investment Advisers lifted its holdings in shares of Phibro Animal Health by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock worth $608,000 after acquiring an additional 293 shares during the last quarter. 1620 Investment Advisors Inc. raised its holdings in Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after acquiring an additional 295 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after purchasing an additional 363 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares in the last quarter. Finally, KBC Group NV purchased a new position in Phibro Animal Health in the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.